Filing Details

Accession Number:
0001610618-22-000081
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-09-19 20:28:21
Reporting Period:
2022-09-15
Accepted Time:
2022-09-19 20:28:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1610618 Cidara Therapeutics Inc. CDTX Biological Products, (No Disgnostic Substances) (2836) 461537286
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1787403 Preetam Shah 6310 Nancy Ridge Drive
Suite 101
San Diego CA 92121
Cfo & Cbo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-09-15 50,000 $0.00 166,431 No 4 M Direct
Common Stock Disposition 2022-09-19 15,642 $0.77 150,789 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2022-09-15 50,000 $0.00 50,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2022-09-30 No 4 M Direct
Footnotes
  1. The Reporting Person was previously granted restricted stock units to vest upon the achievement of certain milestone events that occurred on September 15, 2022.
  2. Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2022.
  3. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on September 15, 2022. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  4. Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer.
  5. On September 1, 2021, the Reporting Person was granted restricted stock units totaling 50,000 shares subject to vesting upon the achievement of various milestones.